Alcon's 2025 AGM: A Game Changer for Eye Care Investors!

Ladies and gentlemen, buckle up! Alcon, the global leader in eye care, is about to shake things up with its 2025 Annual General Meeting (AGM) on May 6, 2025. This isn't just another corporate meeting; it's a chance for shareholders to get in on the ground floor of some groundbreaking changes. Let's dive in!



First things first, Alcon is welcoming shareholders to its third in-person AGM since becoming an independent, standalone company. This is a big deal because it shows that Alcon is serious about transparency and engagement. They want to hear directly from their shareholders, and that's something you don't see every day!

Now, let's talk about the elephant in the room: the proposed election of Deborah Di Sanzo to the Board of Directors. This woman is a powerhouse! With over thirty years of experience in technology and healthcare, she's got the chops to drive Alcon's innovation engine. She's the president of Best Buy Health, where she's been focusing on health technology to enable care at home. Imagine that—cutting-edge tech making healthcare more accessible. Plus, she's an instructor at Harvard T.H. Chan School of Public Health and has been on the board of AstraZeneca since 2017. This is a no-brainer! Deborah Di Sanzo is exactly the kind of leadership Alcon needs to stay ahead of the curve.

But wait, there's more! Alcon is proposing a gross dividend of CHF 0.28 in cash per share. That's a 16% increase in core diluted EPS to $3.5, folks! This is a clear sign that Alcon is confident in its financial health and future growth. The company reported a record $1.6 billion in free cash flow for 2024, and they're projecting a 6% to 8% constant currency sales growth for 2025. This dividend, combined with a $750 million share repurchase program over the next three years, shows that Alcon is committed to delivering value to its shareholders.



Now, let's talk about the agenda. There are some big items on the table, including the approval of the operating and financial review, the discharge of the Board of Directors and the Executive Committee, and the appropriation of earnings and declaration of dividend. But the real meat and potatoes are the votes on the compensation of the Board of Directors and the Executive Committee, and the re-election and election of the Chair and the Members of the Board of Directors. This is where the rubber meets the road, folks!

And let's not forget about the proposed dividend. A gross dividend of CHF 0.28 in cash per share is a solid return for shareholders. The first trading day ex-dividend is expected to be May 13, 2025 (for shares held through SIX SIS) and May 14, 2025 (for shares held through DTC), with the payout date in Switzerland expected to be on or around May 15, 2025. The Swiss withholding tax of 35% will be deducted from the gross dividend amount. This is a clear sign that Alcon is committed to delivering value to its shareholders.

So, what does all this mean for you, the investor? It means that Alcon is positioning itself for growth, innovation, and shareholder value. The proposed election of Deborah Di Sanzo, the strong financial performance, and the commitment to shareholder returns make Alcon a stock you need to own. Don't miss out on this opportunity to be part of the future of eye care!

BOO-YAH! Alcon is on fire, and you need to be part of it. Stay tuned for more updates, and get ready to see brilliantly with Alcon!